Phosphate binders in CKD: chalking out the differences

[1]  R. Elashoff,et al.  Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols , 2009, Pediatric Nephrology.

[2]  S. Abrams,et al.  Higher serum 25-hydroxyvitamin D levels in school-age children are inconsistently associated with increased calcium absorption. , 2009, The Journal of clinical endocrinology and metabolism.

[3]  A. Hutchison.  Oral phosphate binders. , 2009, Kidney international.

[4]  C. Giachelli.  The emerging role of phosphate in vascular calcification. , 2009, Kidney international.

[5]  D. Prié,et al.  Latest findings in phosphate homeostasis. , 2009, Kidney international.

[6]  P. Raggi,et al.  How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis? , 2009, Journal of nephrology.

[7]  D. Santoro,et al.  Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. , 2009, Journal of the American Society of Nephrology : JASN.

[8]  S. Kuruğoğlu,et al.  Progression of coronary calcification in pediatric chronic kidney disease stage 5 , 2009, Pediatric Nephrology.

[9]  M. Wolf,et al.  Phosphorus binders and survival on hemodialysis. , 2009, Journal of the American Society of Nephrology : JASN.

[10]  B. Kestenbaum,et al.  Association of serum phosphate with vascular and valvular calcification in moderate CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[11]  R. Foley,et al.  Serum phosphorus levels associate with coronary atherosclerosis in young adults. , 2009, Journal of the American Society of Nephrology : JASN.

[12]  L. Schurgers,et al.  Dialysis Accelerates Medial Vascular Calcification in Part by Triggering Smooth Muscle Cell Apoptosis , 2008, Circulation.

[13]  L. Hofbauer,et al.  The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  T. Cole,et al.  A bimodal association of vitamin D levels and vascular disease in children on dialysis. , 2008, Journal of the American Society of Nephrology : JASN.

[15]  M. Roszkowska-Blaim,et al.  Determinants of the intima–media thickness in children and adolescents with chronic kidney disease , 2008, Pediatric Nephrology.

[16]  D. Milford,et al.  Mineral metabolism and vascular damage in children on dialysis. , 2007, Journal of the American Society of Nephrology : JASN.

[17]  W. Suki,et al.  Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. , 2007, Kidney international.

[18]  F. Dekker,et al.  High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  C. Shanahan,et al.  VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: The Vascular Biology of Calcification , 2007 .

[20]  P. Raggi,et al.  Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. , 2007, Kidney international.

[21]  L. Rees,et al.  Nutrition in children with CRF and on dialysis , 2007, Pediatric Nephrology.

[22]  I. Salusky.  A new era in phosphate binder therapy: what are the options? , 2006, Kidney international. Supplement.

[23]  H. Oflaz,et al.  Coronary artery calcifications in children with end-stage renal disease , 2006, Pediatric Nephrology.

[24]  E. Friedman.  Calcium-based phosphate binders are appropriate in chronic renal failure. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[25]  G. Chertow,et al.  The case against calcium-based phosphate binders. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[26]  A. R. Morton,et al.  Sevelamer Hydrochloride in Peritoneal Dialysis Patients: CA’ Canny but CA’ AWA’ , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[27]  D. Haffner,et al.  A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  P. Raggi,et al.  Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. , 2005, Kidney international.

[29]  S. Daniels,et al.  Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. , 2005, Journal of the American Society of Nephrology : JASN.

[30]  R. Elashoff,et al.  Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. , 2005, Journal of the American Society of Nephrology : JASN.

[31]  Anna Niemirska,et al.  Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. , 2005, Journal of the American Society of Nephrology : JASN.

[32]  B. Kestenbaum,et al.  Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[33]  L. Schurgers,et al.  Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. , 2004, Journal of the American Society of Nephrology : JASN.

[34]  E. Ritz,et al.  Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? , 2004, Kidney international.

[35]  R. Elashoff,et al.  Sevelamer hydrochloride: an effective phosphate binder in dialyzed children , 2003, Pediatric Nephrology.

[36]  P. Raggi,et al.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.

[37]  M. McKee,et al.  Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.

[38]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[39]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  M. Bald,et al.  Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients , 1996, Pediatric Nephrology.

[41]  R. Heaney,et al.  Calcium balance during human growth: evidence for threshold behavior. , 1992, The American journal of clinical nutrition.

[42]  A. Zinsmeister,et al.  Soft tissue calcification in pediatric patients with end-stage renal disease , 1991, Pediatric Nephrology.

[43]  A. Zinsmeister,et al.  Soft tissue calcification in pediatric patients with end-stage renal disease. , 1990 .

[44]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .

[45]  B. Garrett,et al.  A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. , 1999, Clinical nephrology.

[46]  J. Delmez,et al.  Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. , 1996, Kidney international.